An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Trial Profile

An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Delafloxacin (Primary)
  • Indications Gonorrhoea; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 29 Aug 2016 Results published in the Journal of Clinical Pharmacology
    • 09 Oct 2015 Results of this trial were presented at ID Week, the annual meeting of both the Infectious Disease Society of America and the Society for Healthcare Epidemiology of America, according to a Melinta Therapeutics media release.
    • 29 Apr 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top